Median: an alliance in cancer biomarkers

(CercleFinance.com) - Median Technologies jumped 7% on the Paris Bourse on Friday, after sealing an alliance aimed at providing advanced imaging biomarkers for the development of anticancer drugs in precision medicine.


The software developer says it will join forces with PASREL-Imagerie, a French consortium comprising four CEA Paris-Saclay medical imaging research platforms (IDMIT, MIRCen, NeuroSpin and SHFJ).

The aim of the project is to implement advanced imaging biomarkers to better understand the mechanism of action of anti-cancer drugs, and to gather more information on their efficacy during early-phase clinical trials.

While oncology clinical trials today rely on relatively standard image assessments, the association wants to focus, among other things, on molecular imaging biomarkers.

Copyright (c) 2023 CercleFinance.com. All rights reserved.